Trials / Terminated
TerminatedNCT00819169
QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
A Phase 1b/2 Open Label, Dose Escalation Study of AMG 655 in Combination With AMG 479 in Subjects With Advanced, Refractory Solid Tumors
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 89 (actual)
- Sponsor
- NantCell, Inc. · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, 2-part phase 1b/2 study of AMG 655 in combination with AMG 479 to be conducted in the United States and Spain. Part 1 is a dose escalation segment to identify a dose of AMG 655 in combination with AMG 479 that is safe and tolerable. Part 2 will evaluate the safety and estimate the efficacy of AMG 655 at the dose selected in Part 1 in combination with AMG 479 for the treatment of patients with advanced NSCLC (non-squamous histology; squamous histology), CRC, pancreatic cancer, ovarian cancer, and sarcoma.
Conditions
- Colorectal Cancer
- Locally Advanced
- Metastatic Cancer
- Non-Small Cell Lung Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Sarcoma
- Solid Tumors
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AMG 479 | AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1. |
| BIOLOGICAL | AMG 655 | AMG 655 is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR 5. |
Timeline
- Start date
- 2009-01-16
- Primary completion
- 2011-08-10
- Completion
- 2011-08-10
- First posted
- 2009-01-08
- Last updated
- 2024-08-20
- Results posted
- 2024-08-20
Source: ClinicalTrials.gov record NCT00819169. Inclusion in this directory is not an endorsement.